Cuba-Romero Y, Gainza-Santos N, Batista-Santiesteban N, Saltaren-Cobas A, Naranjo-Medina M

Language: Spanish
References: 18
Page: 5-11
PDF size: 48.71 Kb.

ABSTRACT

One of the most important approaches for the development of Leptospira immunogens is to have very well characterized strains by their virulence and which are representative of the circulating serogroups from the clinical and veterinarian point of view. All of this allows to guarantee immunogens capable to protect against the serovars present in the formulation and that affect animals at risk. This paper was carried out from isolations of the causal agent of five autochthonous clinical cases of Leptospira at Holguín, by means of phenotypic conventional methods: growth at 13ºC, in supplemented media with 8-azaguanina and in the presence of sodium chloride. The isolations were also classified until serogroup level by the microaglutination technique. A strain of Ballum serogroup was selected and characterized from these isolations as a vaccinal candidate. The isolations did not show growth at 13ºC, not even when 8-azaguanina (2.25 mg/mL) was added to the culture, while all the strains showed conversion to spherical form in the presence of sodium chloride (1M). The classification of the isolations allowed having two strains belonging to the serogroup Ballum and two to Pomona. The selected strain showed high virulence and pathogenicity in the Syrian Hamster bio model, as well as a good stability in the culture media. Its classification until the serovar level by means of the use of monoclonal antibodies determined that it belonged to the Ballum serovar. The present paper sets for the first-time the bases for novel vaccinal formulations in animals, containing the serogroup Ballum.

REFERENCES

1. Haake DA, Levett PN. Leptospirosis in humans. Current Topics in Microbiology and Immunology. 2015;387: 65-97.

2. Teresa PP. Leptospirosis animal en Cuba. En: Congreso Internacional de Leptospirosis, Sifi lis y Borreliosis: Espiroquetas. Palacio de las Convenciones, La Habana, 5-7 de mayo, 2010. La Habana. IPK; 2010:10-1.

3. González M, Martínez R, Cruz R, Infante J, González I, Baró M et al. vax-SPIRAL®. Vacuna antileptospirósica trivalente para uso humano, investigación, desarrollo e impacto sobre la enfermedad en Cuba. Biotec Aplic 2004;2(2):107-11.

4. Korthof G. Experimentalles schlammfi eber beim menschen. Zentr Bakteriol Parasitenk Abt I Orig A 1932;125:429-32.

5. Fletcher W. Recent work on leptospirosis, tsutsugamushi disease and tropical typhus in the Federated Malay States. Trans Roy Soc Trop Med Hyg 1928;21:265-82.

6. Faine S. Guidelines for the control of leptospirosis. Geneva: WHO;1982.

7. Cole J, Sulzer C, Pursell A. Improved microtechnique for the leptospiral microscopic agglutination test. Appl Microbiol 1973;5:65-9.

8. Rodríguez I, Obregón A, Rodríguez J, Fernández C, Arzola A, Victoria B. Caracterización serológica de cepas aisladas de pacientes con leptospirosis humana en Cuba. Rev Cub Hig Epidemiol 2002;40(1):11-5.

9. González A, Batista N, Valdés Y, González M. Crecimiento, virulencia y antigenicidad de Leptospira interrogans serovar mozdok en medio EMJH modifi cado. Rev Cub Med Trop 2002;54(1):32-6.

10. Reed LJ, Muench H. A simple method of estimating fi fty percent endpoints. Am J Hyg. 1938;27(3):493-7.

11. Gallegos A, Sandí V. Leptospirosis. Rev Med Costa Rica Centroam 2010;592:115-21.

12. Picardeau M, Bulach D, Bouchier C, Zuerner R, Zidane N, Wilson P, et al. Genome sequence of the saprophyte Leptospira bifl exa provides insights into the evolution of Leptospira and the pathogenesis of leptospirosis. PLoS ONE 2008;3:1599-1607.

13. González A. Evaluación de la potencialidad vacunal de dos cepas de Leptospira interrogans serogrupo Ballum. [Tesis de Maestría]. La Habana: Facultad de Biología, Universidad de La Habana; 2003.

14. Obregón AM, Fernández C, Rodríguez I, Rodríguez J, Zamora Y. Avances de laboratorio en el diagnóstico serológico y la investigación de la leptospirosis humana en Cuba. Rev Cub Med Trop 2007;59(1):1-7.

15. Fajardo E, Ortiz B, Chávez A, Gainza N, Izquierdo L, Hernández Y, et al. Estandarización de la dosis 50 de las cepas de Leptospira interrogans utilizadas en el control de la vacuna cubana contra la leptospirosis humana. Rev Cub Med Trop 1998;50(1):22-6

16. Colleen L, Lau C, Smythe L, Weinstein P. Leptospirosis: An emerging disease in travellers, Travel Medicine and Infectious Diseases 2010;8(1):33-9.

17. Choy HA, Kelley MM, Chen TL, Moller AK, Matsunaga J, Haake DA. Physiological osmotic induction of Leptospira interrogans adhesion: LigA and LigB bind extracellular matrix proteins and fi brinogen. Infect Immun 2007;75(5):2441-50.

18. Croda J, Figueira C, Wunder E, Santos C, Reis M, Ko AI, et al. Targeted mutagenesis in pathogenic Leptospira: disruption of the LigB gene does not affect virulence in animal models of leptospirosis. Infect Immun 2008;76(12):5826-33.